Skip to main content

Table 1 Clinical characteristics in the study groups. Cell count is n/μl CSF (reference range < 4 /μl). Albumin is mg/l (reference range < 400 mg/l)

From: Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

Patient no. Disease phase CSF cell count CSF Albumin
Polynuclear Mononuclear
1 Acute phase 31 43 560
After treatment 0 2 259
2 Acute phase 445 80 3132
After treatment 0 15 215
3 Acute phase 364 80 2546
After treatment 2 37 143
4 Acute phase 310 12 665
After treatment 46 4 211
5 Acute phase 9000 900 1650
After treatment missing missing 1710
6 Acute phase 3400 744 missing
After treatment 17 60 361